the plasma of patients with lung cancer, and to investigate the associations between the expression level of sPD-L1 and clinicopathological features as well as effective and survival outcomes. Method: A total of 200 patients with non-small cell lung cancer (NSCLC)(n¼188) and small cell lung cancer(SCLC)(n¼12) treatment naive were explored, 96 samples of healthy subjects and 13 samples of benign tumours were studied as control. The sPD-L1 expression was scored by the way of anenzyme-linked immunosorbent assay (ELISA). We followed up 67 patients with NSCLC before and after standard treatment, and blood samples were taken every two months. We compared sPD-L1 expression with clinicopathological features and patients outcomes. Result: The Expression of sPD-L1 in patients of lung cancer was significantly higher than benign tumour group and healthy group (3.01±3.00ng/ml, 1.76±1.74ng/ml, 1.82±1.20ng/ml, P¼0.002). The level of sPD-L1 in lung cancer was not associated with gender, age, smoking history, and histologic subtypes (P＞0.05). The level of sPD-L1 was significantly higher in patients of worse PS (performance status)(PS!2) than better PS(PS<2) (6.40±6.53 vs. 2.68±2.06 P¼0.005). The level of sPD-L1 with later stages were remarkable higher than earlier stages (P<0.001) in NSCLC patients. The expression of sPD-L1 of the patients with epidermal growth factor (EGFR) mutated adenocarcinoma was higher than EGFR-wild group (4.30±1.82ng/ml vs. 3.76±1.57ng/ml, P¼0.271). The decline of the level of sPD-L1 was correlated with the effects of good response and progressive disease (PD)(0.49±1.48ng/ml vs. 0.11±0.52ng/ml, P¼0.307). As for survival, there was no difference between the decline of level of sPD-L1 and the progress free survival (PFS). Conclusion: Our results indicated that the elevated expression of sPD-L1 of patients with NSCLC was associated with later stages and worse life conditions, and which may correlated with bad clinical response and poor prognosis. EGFR mutation status may affect the expression of sPD-L1. Further studies are needed to determine the role of sPD-L1 as a molecular prognosis marker for the treatment and prognosis of patients with lung cancer. Keywords: lung cancer, nonsmall cell lung cancer (NSCLC), Soluble programmed death-ligand 1(sPD-L1)
P2.01-94 Diagnostic Patterns of Non-Small Cell Lung Cancer at Princess Margaret Cancer Centre M. Sung, M. Nadjafi, G. Santos, L. Le, D. Hwang, M. Tsao, N. Leighl Princess Margaret Cancer Centre, Toronto, ON/CA Background: Accurate classification of lung cancer subtypes has become critical in tailoring lung cancer treatment. Our study aimed to evaluate changes in diagnostic testing and pathologic subtyping of advanced non-small cell lung cancer (NSCLC) over time at a major cancer centre. Method: A review of patients diagnosed with advanced NSCLC at the Princess Margaret Cancer Centre between 2007-2009 and 2013-2015 was performed. Diagnostic method, sample type and site, pathologic subtype, and use of immunohistochemical (IHC) staining and molecular testing were abstracted. Result: A total of 238 patients were reviewed in 2007-2009 and 283 patients in 2013-2015 (Table 1) . Over time, the proportion of patients diagnosed with adenocarcinoma increased from 60.9% to 73.1% while NSCLC-not otherwise specified (NOS) diagnosis decreased from 18.9% to 6.4%, p<0.0001. There was a decrease in use of diagnostic bronchoscopy (26.9% vs 18.4%) and an increase with mediastinal sampling procedures including endobronchial ultrasound (9.2% vs 20.5%), p¼0.0001. A substantial reduction in cases reported as NSCLC-NOS was observed among bronchoscopy, image-guided, and mediastinal sampling procedures. The reduction in NSCLC-NOS was also predominantly seen in cytology samples, from 22.0% to 4.0% (p<0.0001). IHC use increased over time from 41.6% to 76.3% (p<0.0001). Patients with larger samples and IHC analysis were more likely to have biomarker testing performed (both p<0.01). Within the group diagnosed with NSCLC-NOS, the use of IHC increased non-significantly from 64% (29/45) to 94% (16/18). With the exception of bronchoscopy samples, use of IHC increased significantly with each method of diagnosis and sample type. Conclusion: Customizing treatment based on pathologic subtype and molecular genotype has become key in treating advanced lung cancer patients. Greater accuracy of pathologic diagnosis is being achieved including through use of routine IHC.
Keywords: diagnostic testing, pathologic subtype, Immunohistochemistry P2.01-95 Assesment the Fitness for Chemotherapy of NSCLC Patients using 6MWT Z. Szalai, A. Szip} ocs, K. Potyó, Z. Szász, T. Molnár Pulmonology, Petz Aladár County Teaching Hospital Gy} or, Gy} or/HU Background: Decision making in chemotherapy in multimorbid advanced NSCLC patients is a complex and challenging task. Physcian reported ECOG performance status (PS), being reproducible, is the gold standard of functional status quantification, when planning an oncology treatment. Inaccurate assesment of PS score is associated with an increased risk of treatment complications and therapy related deaths. The aim of study was to measure the correlation between 6-minute walking test (6MWT), PS and chemotherapy endurance and to study the role of 6MWT in predicting treatment complications and deaths. Method: 138 advanced stage (IIIA, IIIB, IV) NSCLC consented patients were enrolled in a prospective study. They were grouped according to their 6MWT results, and correlation with PS, BMI, FEV1, laboratory values, chemotherapy regimes and cycles were analyzed, with respect to the treatment complications and deaths as endpoints. Statistical
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